Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buspirone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Recipient : Cingulate Therapeutics, LLC
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.
Brand Name : CTx-2103
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : Buspirone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Recipient : Cingulate Therapeutics, LLC
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?